Osteopenia Completed Phase 1 Trials for Risedronic acid (DB00884)

Also known as: Osteopaenia / Bone loss

IndicationStatusPhase
DBCOND0015922 (Osteopenia)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00577850Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose